22.74
0.22%
0.104
전일 마감가:
$22.64
열려 있는:
$22.74
하루 거래량:
161.97K
Relative Volume:
0.21
시가총액:
$1.60B
수익:
$80.89M
순이익/손실:
$-144.73M
주가수익비율:
-7.6579
EPS:
-2.97
순현금흐름:
$-83.87M
1주 성능:
-15.52%
1개월 성능:
-10.95%
6개월 성능:
+42.35%
1년 성능:
+267.75%
누릭스 테라퓨틱스 Stock (NRIX) Company Profile
명칭
Nurix Therapeutics Inc
전화
(415) 660-5320
주소
1700 OWENS STREET, SUITE 205, SAN FRANCISCO
NRIX을(를) 다른 주식과 비교
주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
---|---|---|---|---|---|---|
NRIX | 22.68 | 1.60B | 80.89M | -144.73M | -83.87M | -2.97 |
VRTX | 448.33 | 115.74B | 10.63B | -479.80M | -1.35B | 13.33 |
REGN | 744.03 | 81.65B | 13.85B | 4.65B | 3.32B | 35.06 |
ARGX | 590.33 | 34.86B | 1.86B | -40.29M | -1.28B | -4.16 |
ALNY | 249.50 | 32.09B | 2.09B | -332.26M | 16.06M | -4.14 |
BNTX | 103.75 | 24.49B | 3.30B | -501.07M | 1.03B | 11.54 |
누릭스 테라퓨틱스 Stock (NRIX) Upgrades & Downgrades
날짜 | 액션 | 분석자 | 등급 변경 |
---|---|---|---|
2024-07-31 | 개시 | Truist | Buy |
2023-06-26 | 재개 | Oppenheimer | Outperform |
2023-03-09 | 개시 | Barclays | Overweight |
2023-02-28 | 개시 | Oppenheimer | Outperform |
2022-10-11 | 개시 | Morgan Stanley | Equal-Weight |
2022-05-31 | 업그레이드 | Wells Fargo | Equal Weight → Overweight |
2022-02-10 | 개시 | Wells Fargo | Equal Weight |
2021-12-29 | 개시 | H.C. Wainwright | Buy |
2021-10-14 | 개시 | SVB Leerink | Outperform |
2021-06-04 | 재개 | Robert W. Baird | Outperform |
2021-04-30 | 재개 | Piper Sandler | Overweight |
2021-04-30 | 개시 | RBC Capital Mkts | Outperform |
2021-04-14 | 개시 | Berenberg | Buy |
2020-11-19 | 개시 | Robert W. Baird | Outperform |
2020-08-18 | 개시 | JP Morgan | Overweight |
2020-08-18 | 개시 | Needham | Buy |
2020-08-18 | 개시 | Piper Sandler | Overweight |
2020-08-18 | 개시 | Stifel | Buy |
모두보기
누릭스 테라퓨틱스 주식(NRIX)의 최신 뉴스
Nurix Therapeutics Receives PRIME Designation from the - GlobeNewswire
Nurix's Cancer Drug NX-5948 Secures EMA PRIME Status for Advanced Leukemia Treatment | NRIX Stock News - StockTitan
Amalgamated Bank Has $49,000 Stock Position in Nurix Therapeutics, Inc. (NASDAQ:NRIX) - Defense World
Nurix Therapeutics (NASDAQ:NRIX) Shares Gap DownShould You Sell? - MarketBeat
Sumitomo Mitsui Trust Group Inc. Purchases New Shares in Nurix Therapeutics, Inc. (NASDAQ:NRIX) - MarketBeat
Chevron Corp (CVX-N) QuotePress Release - The Globe and Mail
Mplx LP (MPLX-N) QuotePress Release - The Globe and Mail
Nurix Therapeutics Presents Preclinical Data from Two - GlobeNewswire
Nurix Reports Strong Preclinical Data for Two Novel Autoimmune Disease Treatments | NRIX Stock News - StockTitan
Nurix Therapeutics (NASDAQ:NRIX) Shares Down 8.7%Should You Sell? - MarketBeat
Redmile Group, LLC Expands Stake in Nurix Therapeutics Inc - GuruFocus.com
Significant Stake Increase by Baker Bros. Advisors in Nurix Ther - GuruFocus.com
WASATCH ADVISORS LP Adjusts Stake in Nurix Therapeutics Inc - GuruFocus.com
When the Price of (NRIX) Talks, People Listen - Stock Traders Daily
Conocophillips (COP-N) QuotePress Release - The Globe and Mail
Wellington Management Group LLP Increases Stake in Nurix Therape - GuruFocus.com
Nurix Therapeutics, Inc. (NASDAQ:NRIX) Shares Purchased by International Assets Investment Management LLC - Defense World
ARK Investment Management LLC Has $49.80 Million Position in Nurix Therapeutics, Inc. (NASDAQ:NRIX) - MarketBeat
Nurix Therapeutics stock soars to 52-week high of $27.61 By Investing.com - Investing.com Canada
Morgan Stanley's Strategic Reduction in Nurix Therapeutics Holdi - GuruFocus.com
Nurix Therapeutics (NASDAQ:NRIX) Hits New 1-Year HighHere's Why - MarketBeat
Nurix Therapeutics stock soars to 52-week high of $27.61 - Investing.com India
Subdued Growth No Barrier To Nurix Therapeutics, Inc. (NASDAQ:NRIX) With Shares Advancing 25% - Simply Wall St
Cisco Systems Inc (CSCO-Q) QuotePress Release - The Globe and Mail
The Analyst Verdict: Nurix Therapeutics In The Eyes Of 10 Experts - Benzinga
Nurix Therapeutics' (NRIX) "Buy" Rating Reiterated at Needham & Company LLC - MarketBeat
Nurix Therapeutics Announces Presentations at the 66th American Society of Hematology (ASH) Annual Meeting - GlobeNewswire
Nurix therapeutics' chief legal officer sells $82,250 in stock - Investing.com India
SEC Form 424B5 filed by Nurix Therapeutics Inc. - Quantisnow
Nurix therapeutics' chief legal officer sells $82,250 in stock By Investing.com - Investing.com UK
(NRIX) Technical Pivots with Risk Controls - Stock Traders Daily
Nurix therapeutics CFO Hans van Houte sells $86,083 in stock - Investing.com India
Houte Hans Van Sells 3,546 Shares of Nurix Therapeutics, Inc. (NASDAQ:NRIX) Stock - MarketBeat
Nurix therapeutics CFO Hans van Houte sells $86,083 in stock By Investing.com - Investing.com Australia
Nurix therapeutics chief legal officer sells $139,866 in stock By Investing.com - Investing.com South Africa
Nurix therapeutics chief legal officer sells $139,866 in stock - Investing.com India
Insider Sale: CFO Houte Van Sells Shares of Nurix Therapeutics I - GuruFocus.com
Nurix Therapeutics to Participate in Upcoming Investor Conferences - GlobeNewswire
Companies Like Nurix Therapeutics (NASDAQ:NRIX) Are In A Position To Invest In Growth - Simply Wall St
Nurix therapeutics chief scientific officer sells shares worth $83,536 By Investing.com - Investing.com Australia
Nurix therapeutics chief legal officer sells shares worth over $101k By Investing.com - Investing.com South Africa
Nurix therapeutics chief scientific officer sells shares worth $83,536 - Investing.com
Nurix therapeutics chief legal officer sells shares worth over $101k - Investing.com
Nurix therapeutics CFO Hans van Houte sells $57,554 in stock - Investing.com
Nurix therapeutics CFO Hans van Houte sells $57,554 in stock By Investing.com - Investing.com Australia
Allspring Global Investments Holdings LLC Makes New Investment in Nurix Therapeutics, Inc. (NASDAQ:NRIX) - MarketBeat
Allspring Global Investments Holdings LLC Makes New $3.15 Million Investment in Nurix Therapeutics, Inc. (NASDAQ:NRIX) - Defense World
Magna International Inc (MG-T) QuotePress Release - The Globe and Mail
Nurix Therapeutics, Inc. (NASDAQ:NRIX) Given Average Rating of "Moderate Buy" by Brokerages - MarketBeat
Nurix Therapeutics stock soars to 52-week high of $26.46 By Investing.com - Investing.com Canada
Nurix Therapeutics (NASDAQ:NRIX) Now Covered by UBS Group - Defense World
누릭스 테라퓨틱스 (NRIX) 재무 분석
매출
순이익
현금흐름
주당 순 이익
누릭스 테라퓨틱스 주식 (NRIX) 내부자 거래
내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
---|---|---|---|---|---|---|---|
Ring Christine | Chief Legal Officer |
Nov 04 '24 |
Sale |
25.00 |
3,290 |
82,250 |
28,084 |
자본화:
|
볼륨(24시간):